Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Wino115on Jul 15, 2022 10:20am
126 Views
Post# 34826835

RE:RE:RE:So what if I told you

RE:RE:RE:So what if I told you

Quite a history for that quote. I thought for sure it was Yogi Berra, but it traces to Danish physicists.

https://quoteinvestigator.com/2013/10/20/no-predict/#:~:text=It%20is%20difficult%20to%20make%20predictions%2C%20especially%20about,is%20hard%20to%20prophecy%2C%20particularly%20about%20the%20future.


palinc2000 wrote: OMG my prediction for much higher volume and price has not materialized at least not this morning...
I take comfort in the Chinese proverb
MAKING PREDICTIONS IS VERY HARD ESPECIALLY WHEN ITS ABOUT THE FUTURE  
 

palinc2000 wrote: Dont worry about it....Nobody cares what  an analyst from NBF thinks...
Assuming the broader markets dont crater  tomorrow I think tomorrow will see a more pronounced increase in THTX  SP ...The very few  who wanted out are now out imo ....I expect  much higher volume  also
As Muxlix would say MY CALL .!!!!!


SPCEO1 wrote: that an analyst who follows TH wrote a report today and decided not to mention anything about either the financing or the phase 1a data. Instead, the analyst decided to focus their report first on Egrifta, then NASH and then Trogarzo. I have to admit that cancer did get a brief mention in the "Risk Factors" section where the analyst made this comment: "2) increased focus on drug development as TH makes
progress on its oncology assets".

Obviously, you probably think I am drunk or doinig drugs to say such a ridiculous thing! Sadly, I am completely lucid and am just reporting accurately on how the NBF analyst crafted his THTX report today. 

The blame for this is obviously partly on the analyst but it is apparent the company's failure to maintain a decent relationship with this analyst or any of the others is what leads to such absurdity in the end. You might think the analyst is really stupid but I don't think that is the case. He likely has just had it with how bad TH has been over a long period of time on engaging the capital markets and how they have let the stock price bleed out in recent months in an info vacuum by holding back that phase 1a data for months. TH could have been giving regular updates as the patients they spoke about today moved through the trial. Maybe there was a good reason to not do so, but I am not aware of it. 

$288,000 dollars worth of THTX traded hands today on the great news we got today that significantly derisked the future of the company - that is it! I am not sure how that can actually be true but the depths to which the company's engagement with the capital markets has reached is breathtaking. We thought there was a problem a year ago and two years ago and three years ago and so on. Shareholders asked for a new board memeber with expertise in the capital markets to be added, which they graciously did, but the situation, which seemed like it could not get any worse, has gotten worse still. 

It was a great day for THTX. Too bad so few investors actually noticed.

 




<< Previous
Bullboard Posts
Next >>